Molecular data is increasingly being integrated into clinical practice to guide cancer treatment. For example, the identification of specific genetic mutations can inform the use of targeted therapies, such as tyrosine kinase inhibitors for cancers with EGFR mutations. Molecular profiling is also used to select patients for clinical trials testing new drugs. Additionally, molecular data can help monitor treatment response and detect minimal residual disease (MRD), providing early indications of relapse.
